EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC-ND 4.0

Virologic Failure and Emergent Integrase Strand Transfer Inhibitor Drug Resistance With Long-Acting Cabotegravir for HIV Treatment: A Meta-analysis

Andrea Perez Navarro iD, Cameron T Nutt, Mark J Siedner iD, Suzanne M McCluskey iD, Andrew Hill iD

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciae631 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Andrea Perez Navarro und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Imperial College London, London, United Kingdom. Hauptthemen laut MEDLINE: HIV Infections, Pyridones, Drug Resistance, Viral, HIV Integrase Inhibitors. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, World Health Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The long-acting injectable regimen of cabotegravir plus rilpivirine (CAB/RPV) emerged as an alternative to oral standard-of-care integrase strand transfer inhibitor (INSTI)–based regimens for individuals with adherence challenges or preference for reduced dosing schedules. Although oral INSTI regimens have a high barrier to emergent resistance, less is known about the potency and durability of CAB/RPV.

Methods

We reviewed clinical trial registries, PubMed, EMBASE, and conference abstract databases to identify reports of CAB/RPV for HIV therapy. We abstracted data on virologic failure (VF) and treatment-emergent INSTI resistance at 48 weeks (range: 24–52). We used single-proportion meta-analysis to summarize outcomes in 3 populations: antiretroviral therapy (ART)–naive individuals initiating CAB/RPV following suppression on oral ART, ART-experienced individuals switched to CAB/RPV with virologic suppression, and ART-experienced individuals switched to CAB/RPV with detectable viremia. Cochrane's RoB 2.0 and ROBINS-1 tools assessed risk of bias.

Results

Thirty-three studies (N = 9224) reported VF prevalence. Nineteen studies (N = 5662) reported resistance data. VF prevalence was 1% (95% CI: 1%–3%) in induction-maintenance studies, 1% (1%–2%) in switch-suppressed studies, and 5% (3%–10%) in switch-viremic studies. INSTI resistance prevalence among successfully genotyped participants at failure was 71% (25%–95%), 61% (44%–75%), and 41% (20%–65%) respectively. Dolutegravir cross-resistance was common (64% of those with emergent resistance).

Conclusions

Although VF rates with CAB/RPV were low, INSTI resistance emerged in approximately 40%–70% of individuals experiencing VF. These rates are significantly higher than those for oral INSTI-based regimens. Both individual-level and broader resistance surveillance may be warranted in populations with expanding CAB/RPV use. Clinical Trials Registration. PROSPERO registration CRD42024543919.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPyridonesDrug Resistance, ViralHIV Integrase InhibitorsAnti-HIV AgentsHumansRilpivirineTreatment FailureHIV-1Viral LoadDiketopiperazines

Stichwörter der Autor:innen

HIVantiretroviral therapycabotegravirdrug resistanceintegrase strand trasfer inhibitors

Substanzen

PyridonescabotegravirHIV Integrase InhibitorsRilpivirineAnti-HIV AgentsDiketopiperazines

Autor:innen und Institutionen

  • Faculty of Medicine, Imperial College London, London, United Kingdom.
  • Division of Infectious Diseases, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Clinical Research Department, Africa Health Research Institute, KwaZulu-Natal, South Africa.
  • Department of Pharmacology, University of Liverpool, Liverpool, United Kingdom.

ORCID-Profile: Andrea Perez Navarro, Mark J Siedner, Suzanne M McCluskey, Andrew Hill

Förderung

  • NIAID NIH HHS
  • NHLBI NIH HHS
  • World Health Organization
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Perez Navarro, A., Nutt, C. T., Siedner, M. J., McCluskey, S. M., & Hill, A. (2025). Virologic Failure and Emergent Integrase Strand Transfer Inhibitor Drug Resistance With Long-Acting Cabotegravir for HIV Treatment: A Meta-analysis. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae631

Vancouver

Perez Navarro A, Nutt CT, Siedner MJ, McCluskey SM, Hill A. Virologic Failure and Emergent Integrase Strand Transfer Inhibitor Drug Resistance With Long-Acting Cabotegravir for HIV Treatment: A Meta-analysis. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae631

BibTeX
@article{PerezNavarro2025,
  author = {Perez Navarro, Andrea and Nutt, Cameron T and Siedner, Mark J and McCluskey, Suzanne M and Hill, Andrew},
  title = {Virologic Failure and Emergent Integrase Strand Transfer Inhibitor Drug Resistance With Long-Acting Cabotegravir for HIV Treatment: A Meta-analysis},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciae631}
}
Kostenlos starten →